Olmesartan/Amlodipine Hct

Olmesartan medoxil, the active ingredient in Olmesartan/Amlodipine Hct, is an angiotensin II receptor blocker (ARB) presented as a combination tablet for oral use. It treats hypertension, often in combination with a thiazide diuretic and a calcium‑channel blocker, and is indicated for adults who require multiple mechanisms to control blood pressure.

GNH USA supplies Olmesartan/Amlodipine Hct as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Olmesartan/Amlodipine Hct is used in the management of hypertension, acting on several complementary pathways to lower blood pressure. - Hypertension: provides additive blood‑pressure reduction by combining an ARB, a calcium‑channel blocker and a thiazide diuretic. - Resistant hypertension: offers an option when monotherapy does not achieve target pressures. - Cardiovascular risk reduction: assists in lowering the risk of stroke and myocardial infarction associated with uncontrolled hypertension.

Adverse reactions may range from mild to severe and should be monitored during therapy.

Common Side Effects: - Headache: mild to moderate intensity. - Peripheral edema: swelling of the ankles or lower legs. - Dizziness or light‑headedness, especially after the first doses. - Fatigue: general feeling of tiredness. - Increased urination: due to the diuretic component. - Flushing: transient warmth or redness of the skin.

Serious or Rare Side Effects: - Angio‑edema: rapid swelling of the face, lips, tongue or throat. - Severe hypotension: marked drop in blood pressure causing fainting. - Electrolyte disturbances: significant changes in potassium or sodium levels. - Acute kidney injury: sudden decline in renal function. - Hepatic dysfunction: abnormal liver enzyme elevations. - Blood dyscrasias: rare blood‑cell abnormalities such as agranulocytosis.

Before initiating therapy, clinicians should assess patient history and monitor relevant parameters. - Renal function: evaluate baseline creatinine and eGFR, adjust if impaired. - Electrolytes: check serum potassium and sodium, especially with the thiazide component. - Hepatic status: use caution in patients with liver disease. - Pregnancy: avoid use; teratogenic risk associated with ARBs and thiazides. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store at ambient temperature: keep below 25°C, retain in original packaging, protect from moisture and light.

Olmesartan/Amlodipine Hct may interact with several drug classes; careful review of a patient’s medication list is essential.

Major Interactions (Avoid): - Aliskiren: concurrent use with ARBs can increase risk of renal impairment and hyperkalemia. - Potassium‑saving diuretics or supplements: may cause dangerous hyperkalemia. - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): can raise amlodipine levels.

Moderate Interactions (Monitor Closely): - NSAIDs: may blunt antihypertensive effect and affect renal function. - Lithium: increased lithium levels and risk of toxicity. - Other antihypertensives: additive blood‑pressure lowering may require dose adjustment.